共 72 条
[1]
Raza A(2014)Hepatocellular carcinoma review: Current treatment and evidence-based medicine World journal of gastroenterology : WJG 20 4115-4127
[2]
Sood GK(2009)A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma Cancer Chemother Pharmacol 63 929-935
[3]
Uhm JE(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[4]
Llovet JM(2006)Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor Mol Cancer Ther 5 995-1006
[5]
Albert DH(2014)PDGF receptor signaling networks in normal and cancer cells Cytokine & growth factor reviews 25 273-283
[6]
Demoulin JB(2006)Biology of platelet-derived growth factor and its involvement in disease Mayo Clin Proc 81 1241-1257
[7]
Essaghir A(1999)Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 79 1283-1316
[8]
Alvarez RH(2010)ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways Mol Cancer Ther 9 653-660
[9]
Kantarjian HM(2008)Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway Leukemia 22 138-146
[10]
Cortes JE(2013)Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma Cancer 119 380-387